Gene · 5425
Papers485
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 485
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comprehensive analysis of POLD2 as a potential biomarker for modulating the immune microenvironment and predicting immunotherapy response in lung adenocarcinoma. | J Thorac Dis | 2026 | 42444900 | PubTator, text mining | PubMed |
| [Transcriptomic Profile of the Trastuzumab-Resistant Breast Cancer Cell Line BT-474]. | Mol Biol (Mosk) | 2025 | 41090333 | PubTator, text mining | PubMed |
| Chasing the Ghost Proteome in the Dark Matter. | Mol Cell Proteomics | 2025 | 41033461 | PubTator, text mining | PubMed |
| BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination Therapies. | bioRxiv | 2025 | 40950237 | PubTator, text mining | PubMed |
| Using machine learning to discover DNA metabolism biomarkers that direct prostate cancer treatment. | Sci Rep | 2025 | 40681784 | PubTator, text mining | PubMed |
| Construction and validation of a prognostic model for glioma: an analysis based on mismatch repair-related genes and their correlation with clinicopathological features. | Transl Cancer Res | 2025 | 40530129 | PubTator, text mining | PubMed |
| The identification and prediction of lung adenocarcinoma prognosis using a novel gene signature associated with DNA replication. | Transl Cancer Res | 2025 | 40224989 | PubTator, text mining | PubMed |
| ASO Author Reflections: Clinical and Biological Significance of POLD2 in Lung Adenocarcinoma. | Ann Surg Oncol | 2025 | 40126712 | PubTator, text mining | PubMed |
| DNA Polymerase Delta 2 Activates Cell Cycle in Lung Adenocarcinoma, Leading to High Malignancy and Poor Prognosis. | Ann Surg Oncol | 2025 | 40095310 | PubTator, text mining | PubMed |
| Development of the TP53 mutation associated hypopharyngeal squamous cell carcinoma prognostic model through bulk multi-omics sequencing and single-cell sequencing. | Braz J Otorhinolaryngol | 2025 | 39341197 | PubTator, text mining | PubMed |
| Venom Component Allergen IgE Measurement in the Diagnosis and Management of Insect Sting Allergy. | J Allergy Clin Immunol Pract | 2025 | 39097146 | PubTator, text mining | PubMed |
| Comparative Assessment of the Allergenicity of Hyaluronidases from Polistes dominula (Pol d 2), Vespula vulgaris (Ves v 2), and Apis mellifera Venom (Api m 2). | Toxins (Basel) | 2024 | 39591253 | PubTator, text mining | PubMed |
| Deciphering the ghost proteome in ovarian cancer cells by deep proteogenomic characterization. | Cell Death Dis | 2024 | 39349928 | PubTator, text mining | PubMed |
| Homozygous substitution of threonine 191 by proline in polymerase η causes Xeroderma pigmentosum variant. | Sci Rep | 2024 | 38212351 | PubTator, text mining | PubMed |
| ELM-the Eukaryotic Linear Motif resource-2024 update. | Nucleic Acids Res | 2024 | 37962385 | PubTator, text mining | PubMed |
| Leveraging technology-driven strategies to untangle omics big data: circumventing roadblocks in clinical facets of oral cancer. | Front Oncol | 2023 | 38234400 | PubTator, text mining | PubMed |
| Canonical binding of Chaetomium thermophilum DNA polymerase δ/ζ subunit PolD3 and flap endonuclease Fen1 to PCNA. | Front Mol Biosci | 2023 | 38223238 | PubTator, text mining | PubMed |
| Human Autosomal Recessive DNA Polymerase Delta 3 Deficiency Presenting as Omenn Syndrome. | J Clin Immunol | 2023 | 38099988 | PubTator, text mining | PubMed |
| POLD1 DEDD Motif Mutation Confers Hypermutation in Endometrial Cancer and Durable Response to Pembrolizumab. | Cancers (Basel) | 2023 | 38067377 | PubTator, text mining | PubMed |
| Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes. | Immunotargets Ther | 2023 | 38026089 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5425/papers